If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
278
results.
Updated on
13/11/2026 [06:58:00]
Results 250 to 275 of 278
Absstract of: US20260337637A1
The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating hemoglobinopathies, including sickle cell disease and beta-thalassemia. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics to red blood cell progenitor cells, enabling treatment of hemoglobinopathies, in vivo.
Absstract of: US20260335366A1
Disclosed are methods for treating muscle wasting diseases, such as spinal muscular atrophy, or muscular dystrophies, using matrix bound vesicles (MBV). Compositions for use in treating a muscle wasting disease are also disclosed.
Absstract of: AU2025251614A1
The present invention relates to lipid nanoparticles comprising ginsenoside or a derivative thereof, and use thereof, and, specifically, to: lipid nanoparticles containing vegetable ginsenoside or a derivative thereof included in ginseng or red ginseng, instead of animal cholesterol for the delivery of therapeutic or vaccine nucleic acids; gene-inorganic nanoparticles in which the corresponding lipid nanoparticles are encapsulated, and a preparation method therefor; and a nucleic acid delivery composition comprising same.
Absstract of: US20260335250A1
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
Absstract of: US20260337338A1
The use of novel polyoxyalkylene based compounds as well as the use of compositions including at least one novel polyoxyalkylene based compound and at least one active agent. Preferably the compounds and compositions are used as lipids, preferably in lipid particles or lipid nanoparticles and in pharmaceutical compositions.
Absstract of: US20260335463A1
Nucleic acid payload delivery systems, and related compositions and kits are provided. Aspects of such systems, compositions, and kits include lipid nanoparticle (LNP)—complexed payload DNAs and auxiliary RNAs. In some instances, the DNA and RNA components are part of the same LNP, while in other instances the DNA and RNA components are part of different LNPs. Also provided are methods of making and using such systems, compositions, and kits for the delivery of LNP complexed nucleic acids into cells, such as cells of a subject in vivo.
Absstract of: US20260337251A1
Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.
Absstract of: US20260335358A1
Provided are a Prussian blue composite, and a preparation method and use thereof. The Prussian blue composite includes hollow mesoporous Prussian blue nanoparticles, a liposome coating the hollow mesoporous Prussian blue nanoparticles, and an ammonia borane complex loaded on the hollow mesoporous Prussian blue nanoparticles.
Absstract of: US20260335274A1
Pharmaceutical formulations for nasal administration are disclosed. The pharmaceutical formulation contains a green tea catechin derivative (such as an epigallocatechin-3-gallate-palmitate); and preferably further includes a carbohydrate (such as a polysaccharide); and a pharmaceutically acceptable carrier. The pharmaceutical formulation has a viscosity sufficient to maintain the green tea catechin derivative in contact with nasal epithelial cells optionally for at least about 30 minutes in the presence of mucus. Also described are methods of using the nasal formulations for preventing, reducing, and/or treating neurological damages caused by exposure to a virus, such as a SARS-CoV-2. For example, the disclosed pharmaceutical formulations can treat or prevent one or more symptoms of long COVID in an infected subject, and/or repair the damaged nasal epithelial cells, neuroepithelial cells, vascular cells, and/or neurons and restore their functions in a subject recovered from a COVID infection, such as the olfactory function of these cells.
Absstract of: US20260335237A1
The present disclosure relates to lipids, lipid nanoparticles and formulations thereof, and to methods involving the lipids and lipid nanoparticles to deliver one or more therapeutics and/or prophylactics to and/or produce polypeptides in mammalian cells or organs.
Absstract of: US20260335249A1
The present disclosure relates, in one aspect, to ionizable lipids of Formula (I). In another aspect, the present disclosure relates to the preparation of ionizable lipids of Formula (I). In other aspects, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of Formula (I), at least one neutral lipid, cholesterol, and at least one conjugated lipid, and methods of use thereof.
Absstract of: WO2026222821A1
Disclosed in the present invention are a triboelectric-responsive DNA hydrogel dressing for promoting wound healing, a preparation method therefor, and use thereof. The hydrogel can simultaneously load silver nanoclusters, VEGF, and diclofenac sodium by means of a DNA three-way junction structure containing a cytosine ring, a DNA linker containing a VEGF aptamer sequence, and a cross-linked backbone deposited by polypyrrole. The DNA hydrogel dressing prepared in the present invention utilizes the triboelectric-responsive properties to achieve on-demand drug delivery and promote the healing of bacteria-infected diabetic wounds, and has characteristics such as good biocompatibility, excellent antibacterial performance, fast response speed, and remarkable healing effect. Moreover, the preparation process is simple, low in cost, and easy for large-scale production. Therefore, the present invention helps to solve the problems of insufficient antibacterial performance, poor electrical conductivity, and low healing efficiency of existing wound dressings, and can further expand its application in the treatment of chronic wounds and diabetic wounds, thereby providing an important solution for wound care and infection control.
Absstract of: US20260335251A1
In one aspect, this disclosure relates to nanoparticle compositions comprising a core a plurality of nanoparticles, each nanoparticle of the plurality comprising a core, wherein the core comprises a biocompatible copolymer, and each nanoparticle of the plurality further comprising an ionic liquid coating surrounding the core; methods of making the same; pharmaceutical compositions comprising same; and methods of treating neurological diseases and disorders using same. In one aspect, the biocompatible copolymer can be poly(lactic-co-glycolic acid). In another aspect, the nanoparticle compositions can include one or more pharmaceutical agents including, but not limited to, antiretroviral agents. In still another aspect, the ionic liquids can include choline and an anion derived from a substituted or unsubstituted C2-C20 linear or branched fatty acid. In any of these aspects, the nanoparticle compositions are capable of crossing the blood brain barrier.
Absstract of: US20260335462A1
Provided herein are lipid nanoparticle compositions comprising a cationic lipid, a steroid, a polymer conjugated lipid, and no more than 0.5 mole percent phospholipid, that can be used for delivery of therapeutic payloads (e.g., mRNA, siRNA, DNA) for therapeutic or prophylactic purposes.
Absstract of: US20260335359A1
The present invention relates to a composition for cancer immunotherapy, comprising superparamagnetic nanoparticles as an active ingredient, a composition for treating immune diseases, a composition for enhancing immunity, a composition for suppressing a decrease in immune function or enhancing immune function, the composition being administered in combination with a chemotherapeutic anticancer drug, a composition for suppressing a decrease in immune function, caused by anticancer treatment or enhancing immune function, and a composition for ameliorating, treating or preventing decreased immune responses in individuals with cancer. The superparamagnetic nanoparticles according to the present invention have magnetically-induced heating characteristics and high biocompatibility, thus being applicable through in vivo injection, and can induce an increase in immune cells, thus being effectively used in the treatment of cancer and immune diseases.
Absstract of: US20260335248A1
This application relates generally to methods of treating or preventing mucormycosis in a subject in need thereof using, inter alia, encochleated oral formulations of amphotericin B.
Absstract of: US20260335376A1
A composition of matter for treating inflammatory bowel diseases (IBDs) and a corresponding method for treating IBDs. The composition of matter includes a reactive oxygen species (ROS) scavenger conjugated to a probiotic. The method includes administering the composition of matter to a subject in an anti-IBD-effective amount.
Absstract of: US20260335351A1
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Absstract of: US20260335287A1
Method and compositions that comprise an agent that reduces nNOS activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.
Absstract of: WO2026227084A1
A method of synthesising gold nanoparticles for treating breast cancer is provided The gold nanoparticles are synthesised by a process which comprises adding an aqueous Dodonaea viscosa leaf extract to a solution containing gold ions, such as gold (III) chloride hydrate. Phytochemicals in the aqueous extract reduce the gold ions, leading to the formation of gold nanoparticles which are capped with compounds from the extract. The nanoparticles are stable and are capable of inhibiting the growth of breast cancer cells in vitro and significantly reducing tumour size in vivo, while having little effect on non-cancerous cells. Gold nanoparticles produced by the method, a composition comprising the gold nanoparticles and a method of treating breast cancer are also described.
Absstract of: WO2026222691A1
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules encoding gene editing machinery) for therapeutic or prophylactic purposes.
Absstract of: WO2026226739A1
The present disclosure provides a nanoparticle complex comprising (a) a lipid nanoparticle comprising a non-sheddable surface component and a sheddable surface component, and (b) a bifunctional binder comprising a self-binder moiety non-covalently binding to the non-sheddable surface component and a target-binder moiety capable of binding to a targeted cell-surface component of a target cell.
Absstract of: AU2026253888A1
METHOD FOR TREATING OSTEOARTHRITIS WITH A COMBINATION OF MESENCHYMAL STEM CELL EXOSOMES, SYNOVIAL MESENCYMAL STEM CELLS, AND SCAFFOLDS Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device; covering articular cartilage in an affected joint with a scaffold; and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells. ct c t
Absstract of: WO2020097540A1
The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.
Nº publicación: US20260337552A1 29/10/2026
Applicant:
ILLUMINA INC [US]
ILLUMINA, INC.
Absstract of: US20260337552A1
Embodiments of systems, methods, and compositions provided herein relate to hollow encapsulating single cells. Some embodiments include performing multiple co-assays single cell encapsulated within a hollow bead, including nucleic acid sequencing, preparing nucleic acid libraries, determining methylation status, identifying genomic variants, or protein analysis.
BOPI
Electronic site
